OBJECTIVE: To investigate if adjunctive valacyclovir, an antiviral medication, reduces symptoms of persistent schizophrenia in individuals who are seropositive for cytomegalovirus (CMV). METHOD:N=47 CMV seropositive schizophrenia outpatients were randomly assigned to receive valacyclovir 1 g twice daily (n=24) or placebo (n=23) for 16 weeks after a 2-week placebo run-in. Symptoms were assessed biweekly. RESULTS: There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between the valacyclovir vs. the placebo group. CONCLUSIONS: The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.
RCT Entities:
OBJECTIVE: To investigate if adjunctive valacyclovir, an antiviral medication, reduces symptoms of persistent schizophrenia in individuals who are seropositive for cytomegalovirus (CMV). METHOD: N=47 CMV seropositive schizophrenia outpatients were randomly assigned to receive valacyclovir 1 g twice daily (n=24) or placebo (n=23) for 16 weeks after a 2-week placebo run-in. Symptoms were assessed biweekly. RESULTS: There was no significant difference in the change of positive, negative, general, or total PANSS symptoms between the valacyclovir vs. the placebo group. CONCLUSIONS: The study did not demonstrate benefit of adjunctive valacyclovir for schizophrenia individuals with persistent symptoms who are CMV seropositive.
Authors: Manish Kumar; Herbert E Kaufman; Christian Clement; Partha S Bhattacharjee; Tashfin S Huq; Emily D Varnell; Hilary W Thompson; James M Hill Journal: Invest Ophthalmol Vis Sci Date: 2010-04-14 Impact factor: 4.799
Authors: Thomas A Pollak; Jonathan P Rogers; Robert G Nagele; Mark Peakman; James M Stone; Anthony S David; Philip McGuire Journal: Schizophr Bull Date: 2019-01-01 Impact factor: 9.306